EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
← Back to the desk

Restrictions / RESEARCH BRIEFING

Does adding B12 establish permission to compound semaglutide?

An additional ingredient is a fact to review, not a procurement shortcut.

THE FINDING

An ingredient change alone should never generate a green clearance result.

Affected arrangements: Proposals for semaglutide combinations or other changes claimed to distinguish a compounded product.

Record the actual proposal

List the active ingredients, dosage form, presentation and reason the supplier gives for the change. Preserve the exact wording of any claim that adding an ingredient establishes permission. Do not treat marketing terms such as personalised as a substitute for evidence. Procurement should document the assertion and its owner without endorsing it.

Read the applicable distinction

FDA's 1 April 2026 policy update discusses essential-copy considerations, including semaglutide and vitamin B12 combinations. It also describes a prescriber-documented significant difference for an identified individual patient in the section 503A context. That is a qualified legal and clinical question; a generic ingredient checkbox does not resolve it.

Keep patient information out of the research tool

The desk can organise business evidence and questions, but it should not receive clinical records, prescription images or identifiers. Any patient-specific assessment belongs in the provider's appropriate clinical and legal processes. Request confirmation that the necessary review exists without uploading the underlying patient material into a procurement tool.

Hand off the unresolved questions

Ask counsel which conditions apply to the asserted pathway and proposed supply. Ask the clinical lead to review the claimed clinical basis through the right process. Record a deadline, responsible reviewer and consequence for the commercial decision. Until those questions are resolved, leave the comparison marked assessment incomplete and avoid modelling savings as an actionable recommendation.

Questions to take forward

  • What specific distinction does the supplier claim?
  • Who has reviewed that distinction for this arrangement?
  • What business evidence can be retained without patient information?
Put this briefing to work

Primary sources & evidence limits

FDA: GLP-1 compounding policies and dated shortage milestones ↗Latest dated update retrieved: 1 April 2026 · Accessed 2026-11-17FDA: Concerns with unapproved GLP-1 drugs ↗Publication date not confirmed · Accessed 2026-11-17

Primary-source links were opened or retrieved on 17 November 2026. This date records source access, not legal or clinical review. Procurement checklists and commercial models are editorial methods. No live supplier, licence, coverage or capacity verification has been performed.

Read the research methodology →